Senolytic Peptide
Cellular Renewal at the Molecular Level
Researched for clearing senescent cells. Join our waitlist to be notified when available.
100+
Preclinical Studies
50%+
Senescent Cell Reduction
2019
Breakthrough Discovery
D-Retro
Inverso Technology
Coming Soon
FOXO4-DRI will be available through our medical team. Join the waitlist to be notified when we launch.
Research-grade senolytic dosage
Ideal For
Those seeking cutting-edge cellular senescence intervention, longevity optimization, and age-related cellular health support.
The Science
FOXO4-DRI (D-Retro-Inverso) is a novel senolytic peptide that selectively targets and eliminates senescent cells—aged, dysfunctional cells that accumulate in tissues and contribute to age-related decline and disease.
This innovative peptide works by disrupting the interaction between FOXO4 and p53 proteins within senescent cells. By interfering with this survival pathway, FOXO4-DRI induces apoptosis specifically in senescent cells while leaving healthy cells unaffected.
Originally developed through groundbreaking research at Erasmus University Medical Center, FOXO4-DRI represents a targeted approach to cellular rejuvenation and has shown remarkable promise in preclinical studies for promoting healthspan and addressing age-related cellular dysfunction.
Join the Waitlist
How It Works
FOXO4-DRI employs a sophisticated molecular approach to selectively eliminate senescent cells through targeted protein disruption.
The peptide specifically identifies and binds to senescent cells through recognition of FOXO4 transcription factors.
FOXO4-DRI interrupts the interaction between FOXO4 and p53, destabilizing the survival mechanisms of senescent cells.
Once the pathway is disrupted, senescent cells undergo programmed cell death while healthy cells remain protected.
Clinical Benefits
Targets and eliminates senescent cells that accumulate with age and contribute to tissue dysfunction.
Research suggests senolytic intervention may support healthspan extension and age-related resilience.
May support improved tissue function by reducing the senescence-associated secretory phenotype (SASP).
Senescent cells secrete pro-inflammatory factors; their removal may support balanced inflammatory response.
Preclinical data suggests potential benefits for metabolic health markers and cellular energy production.
May support improved recovery and adaptation by reducing cellular burden from accumulated senescent cells.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Complete our waitlist form to be notified when FOXO4-DRI becomes available.
When available, meet with our physicians for comprehensive evaluation and laboratory testing.
Receive a customized treatment protocol tailored to your individual health profile and goals.
Regular monitoring, follow-up testing, and protocol adjustments ensure optimal outcomes.
Safety & Candidacy
FOXO4-DRI therapy requires careful medical evaluation and is only available under physician supervision. Our team ensures appropriate candidacy through comprehensive screening.
Medical
Supervision required for all protocols
Custom
Individualized dosing and monitoring plans
Questions
Senescent cells are aged, dysfunctional cells that have stopped dividing but resist normal cell death. They accumulate with age and secrete inflammatory factors (SASP) that can damage surrounding healthy tissue, contributing to age-related decline and disease.
FOXO4-DRI uses a unique mechanism targeting the FOXO4-p53 interaction specifically within senescent cells. Unlike broad-spectrum approaches, this peptide’s D-retro-inverso structure provides enhanced stability and selectivity, minimizing effects on healthy cells.
Protocols are highly individualized based on patient health status, goals, and response. Our physicians design customized treatment schedules that may range from single courses to periodic interventions with comprehensive monitoring throughout.
Comprehensive laboratory testing is performed before treatment initiation and at regular intervals. This includes cellular health markers, inflammatory markers, metabolic panels, and other relevant biomarkers to ensure safety and track therapeutic response.
FOXO4-DRI is not FDA approved. It is available through compounding pharmacies for use in physician-supervised research and clinical protocols. All treatment is provided under medical oversight with comprehensive informed consent.
Ideal candidates are adults seeking cutting-edge longevity interventions who are in generally good health and can commit to comprehensive monitoring. A thorough medical evaluation determines individual candidacy based on health status, goals, and contraindications.
We are currently finalizing our protocols and sourcing relationships. Join our waitlist to be among the first notified when FOXO4-DRI becomes available through our medical team. We anticipate launching within the coming months.
Join the Waitlist
Join our waitlist to be notified when FOXO4-DRI becomes available. Our medical team will reach out to schedule your consultation.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. FOXO4-DRI is not FDA approved and is available only through compounding pharmacies for use in physician-supervised protocols. Senolytic peptide therapy is an emerging field with ongoing research; long-term safety and efficacy in humans have not been fully established. Individual results may vary. A consultation with our medical team and comprehensive laboratory testing are required to determine if this therapy is appropriate for you.
